CCN6 regulates IGF2BP2 and HMGA2 signaling in metaplastic carcinomas of the breast
- 215 Downloads
Metaplastic breast carcinomas are an aggressive subtype of triple-negative breast cancer (TNBC) in which part or all of the adenocarcinoma transforms into a non-glandular component (e.g., spindled, squamous, or heterologous). We discovered that mammary-specific Ccn6/Wisp3 knockout mice develop mammary carcinomas with spindle and squamous differentiation that share upregulation of the oncofetal proteins IGF2BP2 (IMP2) and HMGA2 with human metaplastic carcinomas. Here, we investigated the functional relationship between CCN6, IGF2BP2, and HMGA2 proteins in vitro and in vivo, and their expression in human tissue samples.
MMTV-cre;Ccn6fl/fl tumors and spindle TNBC cell lines were treated with recombinant CCN6 protein or vehicle. IGF2BP2 was downregulated using shRNAs in HME cells with stable CCN6 shRNA knockdown, and subjected to invasion and adhesion assays. Thirty-one human metaplastic carcinomas were arrayed in a tissue microarray (TMA) and immunostained for CCN6, IGF2BP2, and HMGA2.
CCN6 regulates IGF2BP2 and HMGA2 protein expression in MMTV-cre;Ccn6fl/fl tumors, in MDA-MB-231 and − 468, and in HME cells. CCN6 recombinant protein reduced IGF2BP2 and HMGA2 protein expression, and decreased growth of MMTV-cre;Ccn6fl/fl tumors in vivo. IGF2BP2 shRNA knockdown was sufficient to reverse the invasive abilities conferred by CCN6 knockdown in HME cells. Analyses of the TCGA Breast Cancer Cohort (n = 1238) showed that IGF2BP2 and HMGA2 are significantly upregulated in metaplastic carcinoma compared to other breast cancer subtypes. In clinical samples, low CCN6 is frequent in tumors with high IGF2BP2/HMGA2 with spindle and squamous differentiation.
These data shed light into the pathogenesis of metaplastic carcinoma and demonstrate a novel CCN6/IGF2BP2/HMGA2 oncogenic pathway with biomarker and therapeutic implications.
KeywordsBreast cancer CCN6 WISP3 IGF2BP2 HMGA2 Metaplastic
We thank all members of the Kleer laboratory for helpful discussion. We thank Tina Fields from the Histology laboratory for assistance with immunostaining.
This work was supported by National institutes of Health (NIH) Grants R01CA125577 and R01CA107469 (C.G.K.), and the University of Michigan Rogel Cancer Center support Grant P30CA046592.
Compliance with ethical standards
Conflict of interest
Dr. Dafydd Thomas is consultant of Resonant Therapeutics. The other authors have no conflicts of interest.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed University of Michigan UCUCA protocol #: PRO00006984 (approval date 6/23/2016, expiration date 6/23/2019).
Human and animal rights
This article does not contain any studies with human participants performed by any of the authors.
- 2.Rakha EA, Tan PH, Varga Z, Tse GM, Shaaban AM, Climent F, van Deurzen CH, Purnell D, Dodwell D, Chan T, Ellis IO (2015) Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. Br J Cancer 112(2):283–289. https://doi.org/10.1038/bjc.2014.592 CrossRefPubMedGoogle Scholar
- 5.Song Y, Liu X, Zhang G, Song H, Ren Y, He X, Wang Y, Zhang J, Zhang Y, Sun S, Liang X, Sun Q, Pang D (2013) Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators. World J Surg Oncol 11:129. https://doi.org/10.1186/1477-7819-11-129 CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Pal A, Huang W, Li X, Toy KA, Nikolovska-Coleska Z, Kleer CG (2012) CCN6 modulates BMP signaling via the Smad-independent TAK1/p38 pathway, acting to suppress metastasis of breast cancer. Cancer Res 72 (18):4818–4828. https://doi.org/10.1158/0008-5472.CAN-12-0154 CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Zhang Y, Pan Q, Zhong H, Merajver SD, Kleer CG (2005) Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells. Breast Cancer Res 7(6):R1080–R1089. https://doi.org/10.1186/bcr1351 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Cleynen I, Brants JR, Peeters K, Deckers R, Debiec-Rychter M, Sciot R, Van de Ven WJ, Petit MM (2007) HMGA2 regulates transcription of the Imp2 gene via an intronic regulatory element in cooperation with nuclear factor-kappaB. Mol Cancer Res 5(4):363–372. https://doi.org/10.1158/1541-7786.MCR-06-0331 CrossRefPubMedGoogle Scholar
- 18.Huang W, Gonzalez ME, Toy KA, Banerjee M, Kleer CG (2010) Blockade of CCN6 (WISP3) activates growth factor-independent survival and resistance to anoikis in human mammary epithelial cells. Cancer Res 70 (8):3340–3350. https://doi.org/10.1158/0008-5472.CAN-09-4225 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Gonzalez ME, DuPrie ML, Krueger H, Merajver SD, Ventura AC, Toy KA, Kleer CG (2011) Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer. Cancer Res 71 (6):2360–2370. https://doi.org/10.1158/0008-5472.CAN-10-1933 CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig 121(7):2750–2767. https://doi.org/10.1172/JCI45014 CrossRefPubMedGoogle Scholar
- 25.Weigelt B, Ng CK, Shen R, Popova T, Schizas M, Natrajan R, Mariani O, Stern MH, Norton L, Vincent-Salomon A, Reis-Filho JS (2015) Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected]. Mod Pathol 28(3):340–351. https://doi.org/10.1038/modpathol.2014.142 CrossRefPubMedGoogle Scholar
- 26.Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, Liu W, Stivers D, Baggerly K, Carey M, Lluch A, Monteagudo C, He X, Weigman V, Fan C, Palazzo J, Hortobagyi GN, Nolden LK, Wang NJ, Valero V, Gray JW, Perou CM, Mills GB (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69 (10):4116–4124. https://doi.org/10.1158/0008-5472.CAN-08-3441 CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Ng CKY, Piscuoglio S, Geyer FC, Burke KA, Pareja F, Eberle CA, Lim RS, Natrajan R, Riaz N, Mariani O, Norton L, Vincent-Salomon A, Wen YH, Weigelt B, Reis-Filho JS (2017) The landscape of somatic genetic alterations in metaplastic breast carcinomas. Clin Cancer Res 23(14):3859–3870. https://doi.org/10.1158/1078-0432.CCR-16-2857 CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Rakha EA, Richardson AL, Schmitt FC, Tan PH, Tse GM, Weigelt B, Ellis IO, Reis-Filho JS (2011) Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 24(2):157–167. https://doi.org/10.1038/modpathol.2010.200 CrossRefPubMedGoogle Scholar
- 34.Wend P, Runke S, Wend K, Anchondo B, Yesayan M, Jardon M, Hardie N, Loddenkemper C, Ulasov I, Lesniak MS, Wolsky R, Bentolila LA, Grant SG, Elashoff D, Lehr S, Latimer JJ, Bose S, Sattar H, Krum SA, Miranda-Carboni GA (2013) WNT10B/beta-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer. EMBO Mol Med 5(2):264–279. https://doi.org/10.1002/emmm.201201320 CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Wu J, Zhang S, Shan J, Hu Z, Liu X, Chen L, Ren X, Yao L, Sheng H, Li L, Ann D, Yen Y, Wang J, Wang X (2016) Elevated HMGA2 expression is associated with cancer aggressiveness and predicts poor outcome in breast cancer. Cancer Lett 376 (2):284–292. https://doi.org/10.1016/j.canlet.2016.04.005 CrossRefPubMedGoogle Scholar